When FDA panelists on COX-2 inhibitors have industry ties it’s considered a big story, but when panelists on federal and state immunization panels have ties to vaccine manufacturers few seem to notice or care. Why is one story more newsworthy than the other?
August 31, 2015 08:57 PM by Doug Powers
February 1, 2015 02:29 PM by Doug Powers
August 26, 2014 10:24 AM by Doug Powers
August 15, 2014 01:51 PM by Michelle Malkin
July 23, 2014 08:31 PM by Doug Powers